DOTQUANT LLC
SHORELINE, WA · Biotech · Private
RNA aptamers targeting SARS-CoV-2 spike protein for viral neutralization
- Grants
- $3.8M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · In situ single cell imaging | $216,126 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · In situ single cell imaging | $1,211,534 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · In situ single cell imaging | $605,767 | |
| Federal grant | Department of Health and Human Services · Phase II · In situ single cell imaging | $605,767 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a sensitive and quantitative western blot kit | $256,022 | |
| Federal grant | Department of Health and Human Services · Phase I · SBIR PA22-176 - RNA aptamers for rapid response to COVID-19 variants | $275,482 | |
| Federal grant | Department of Health and Human Services · Phase I · RNA aptamers for rapid response to COVID-19 variants | $275,482 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a WT RNAP-based kit for high-yield synthesis of chemically modified RNA | $305,892 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2723 | Accuronix Therapeutics Inc | — | — |
| 2724 | Alveus Pharma | — | — |
| 2725 | SEVEN BIOSCIENCES, INC. | — | — |
| 2726 | DOTQUANT LLC | — | — |
| 2727 | Metaphore Biotechnologies | — | — |
| 2728 | Cellarity | — | — |
| 2729 | VAXSYNA, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.